SARS-CoV-2 cell entry and targeted antiviral development.
10.1016/j.apsb.2021.05.007
- Author:
Zinuo CHEN
1
;
Ruikun DU
1
;
Jazmin M GALVAN ACHI
2
;
Lijun RONG
2
;
Qinghua CUI
1
Author Information
1. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
2. Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
- Publication Type:Review
- Keywords:
Antiviral development;
Cell entry;
Post-pandemic;
SARS-CoV-2;
Spike protein
- From:
Acta Pharmaceutica Sinica B
2021;11(12):3879-3888
- CountryChina
- Language:English
-
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era.
